We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App





FDA Could Issue Emergency Use Authorization for COVID-19 Vaccine Within Weeks After Clinical Trial Data Meet Efficacy Requirements

By HospiMedica International staff writers
Posted on 05 Aug 2020
The US Food and Drug Administration (FDA Silver Spring, MD, USA) could issue an emergency use authorization (EUA) for a COVID-19 vaccine in a “matter of weeks” after clinical trial data meet efficacy requirements, according to a top FDA official.

The EUA would speed up the process of producing the COVID-19 vaccine and making it available for the public. More...
Speaking at a recent online event called the Disease Control and Prevention Summit, Peter Marks, MD, director of the FDA Center for Biologics Evaluation and Research, which approves vaccines, said “We’d like to hope that when (efficacy) happens, it will be a matter of weeks before we could actually potentially have something like an emergency use authorization.” However, on an FDA podcast called FDA Insight, Marks cautioned that such an authorization was still months away. Referring to two vaccine candidates that had entered into advanced clinical trials and were being tested on a large group of people, Marks said that enrolling people in a trial takes time and the vaccine’s effectiveness would be visible only after months, suggesting that a vaccine would become available several months from now.

Instead of the step-by-step process that was usually followed for developing vaccines in order to reduce the risk of financial investment, multiple steps were currently being funded at the same time to move a COVID-19 vaccine quickly, according to Marks, although safety remained the top priority. Calling the leading vaccines that had just entered advanced clinical trials as “trailblazers”, Marks said that they would provide more information for the next vaccine candidates. Given that more than one vaccine was in advanced clinical trials, Marks said that there was a possibility of multiple options becoming available to the people, with one working better in older adults and another causing fewer side effects among certain groups. In that case, Marks suggested that patients should speak with their doctors to choose the best vaccine option.

“Now, how much of it will be deployed and how long that will take I can’t answer today,” said Marks. “But I know there are teams working on that and they’re trying to make that as quick as possible and to make it make as much sense as possible so that the first vaccine that’s ready to go goes out to the people who need it most and that ultimately everyone who wants to get vaccinated can get vaccinated.”

Related Links:
US Food and Drug Administration (FDA)


Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Temperature Monitor
ThermoScan Temperature Monitoring Unit
Autoclave
Advance
OR Table Accessory
Angular Accessory Rail
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.